NASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis $3.63 +0.05 (+1.40%) (As of 02:50 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Mereo BioPharma Group Stock (NASDAQ:MREO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mereo BioPharma Group alerts:Sign Up Key Stats Today's Range$3.53▼$3.6850-Day Range$3.33▼$4.6252-Week Range$3.17▼$5.02Volume410,158 shsAverage Volume798,801 shsMarket Capitalization$509.14 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingBuy Company OverviewMereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Read More… 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Mereo BioPharma Group Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreMREO MarketRank™: Mereo BioPharma Group scored higher than 60% of companies evaluated by MarketBeat, and ranked 462nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 2 research reports in the past 90 days.Read more about Mereo BioPharma Group's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 9.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.26% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Mereo BioPharma Group has recently decreased by 11.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.26% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Mereo BioPharma Group has recently decreased by 11.43%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.15 News SentimentMereo BioPharma Group has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Mereo BioPharma Group this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $702,832.00 in company stock.Percentage Held by InsidersOnly 4.13% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mereo BioPharma Group's insider trading history. Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MREO Stock News HeadlinesMereo BioPharma Group (NASDAQ:MREO) Sets New 52-Week Low - Here's WhyNovember 17, 2024 | americanbankingnews.comMereo Biopharma Group Plc: Positive Developments and Strong Growth Potential Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)Positive Outlook for Mereo Biopharma Group Plc Amidst Promising Therapeutic Developments and Strong Financial PositionNovember 14, 2024 | markets.businessinsider.comMereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNovember 14, 2024 | globenewswire.comMereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comIs Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds?October 16, 2024 | msn.comMereo BioPharma Group plc (MREO): A Bull Case TheorySeptember 18, 2024 | msn.comSee More Headlines MREO Stock Analysis - Frequently Asked Questions How have MREO shares performed this year? Mereo BioPharma Group's stock was trading at $2.31 at the beginning of the year. Since then, MREO stock has increased by 55.4% and is now trading at $3.59. View the best growth stocks for 2024 here. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc (NASDAQ:MREO) announced its earnings results on Thursday, September, 7th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. Who are Mereo BioPharma Group's major shareholders? Mereo BioPharma Group's top institutional shareholders include Janus Henderson Group PLC (8.80%), Frazier Life Sciences Management L.P. (3.63%), Clearline Capital LP (2.31%) and Acuta Capital Partners LLC (0.90%). Insiders that own company stock include Denise Scots-Knight, Charles Sermon, Christine Ann Fox, John A Lewicki, Alexandra Hughes-Wilson and Deepika Pakianathan. View institutional ownership trends. How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Builders FirstSource (BLDR). Company Calendar Last Earnings9/07/2023Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MREO CUSIPN/A CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$8.00 Low Stock Price Target$7.00 Potential Upside/Downside+109.5%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.86 Quick Ratio4.86 Sales & Book Value Annual Sales$10 million Price / Sales50.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book9.94Miscellaneous Outstanding Shares140,260,000Free Float134,464,000Market Cap$502.13 million OptionableOptionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MREO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.